A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Kura Oncology, Inc.
Baylor College of Medicine
Ipsen
National Cancer Institute (NCI)
Celgene
Acrotech Biopharma Inc.
National Institutes of Health Clinical Center (CC)